Literature DB >> 11817310

Liquid chromatography-mass spectrometry assay of a thiadiazole derivative in mice: application to pharmacokinetic studies.

H Wong1, L Jia, J B Camden, S D Weitman.   

Abstract

Modern atmospheric pressure ionization (API) ion-trap mass spectrometry in connection with fast chromatographic separations using a short narrow-bore C8 column was developed to determine 5-phenyl-3-thioureido-1,2,4-thiadiazole (301029), a novel virus inhibitor in serum. Both 301029 and an internal standard (I.S.) were separated from serum samples by acetonitrile deproteinization and extraction without time-consuming reconstitution. The chromatographic separation was achieved on a C8 reversed-phase narrow-bore column using acetonitrile-water-acetic acid (90:10:0.01, v/v/v) as a mobile phase. The mass spectrometric analysis was performed by atmospheric pressure chemical ionization (APCI) mode with positive ion detection. Single ion monitoring (SIM) scan mode of m/z 237 and 158 was used to quantitatively determine 301029 and I.S., respectively. The low limit of quantitation was 25 ng/ml. The assay exhibited a linear range of 25-2500 ng/ml. Recovery from serum proved to be 100-113%. The precision (C.V.) and accuracy (RE) of the method were 2-12% and 94-112%, respectively. The present method was applied to determine the pharmacokinetic parameters of 301029 following oral administration of the agent to mice at 5 g/kg. The results revealed that the elimination half-life of 301029 was 413 min and the area under serum concentration-time curve was 354 microg/ml/min.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11817310     DOI: 10.1016/s0378-4347(01)00403-0

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  4 in total

1.  Improving cyclodextrin complexation of a new antihepatitis drug with glacial acetic acid.

Authors:  Jennifer L H Johnson; Yan He; Akash Jain; Samuel H Yalkowsky
Journal:  AAPS PharmSciTech       Date:  2017-03-08       Impact factor: 3.246

2.  Oral formulation of a novel antiviral agent, PG301029, in a mixture of gelucire 44/14 and DMA (2:1, wt/wt).

Authors:  Yan He; Jennifer L H Johnson; Samuel H Yalkowsky
Journal:  AAPS PharmSciTech       Date:  2005-04-08       Impact factor: 3.246

3.  A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice.

Authors:  Greg S Gorman; Lori U Coward; Lea Freeman; Pat E Noker; Craig W Beattie; Lee Jia
Journal:  J Pharm Biomed Anal       Date:  2010-06-30       Impact factor: 3.935

4.  Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry.

Authors:  Lee Jia; Hong Wong; Cesario Cerna; Steve D Weitman
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.